Language: BG BG
← Back to results
Active (not recruiting) Phase 4 2025-523549-92-00

Melatonin versus placebo for bipolar disorder - a double blinded randomised controlled trial (The M-bipolar RCT)

Phase 4 – monitoring after market approval
Conditions: Bipolar disorder

Sponsor: Region Hovedstaden

trial.available_in: БГ
Overview
Trial status: Authorised Hamilton D6, Pittsburgh Sleep Quality, Young Mania Rating Scale, Functioning Assessment Short Test (FAST), internet-based Cognition Assessment Tool (ICAT) and bloodbased inflammation markers in bloodsamples, hair cortisol and urine oxidative stress markers Mood stabilization will be measured by a mood instability score reflecting the daily variability in self-monitored mood collected via the Monsenso system
Description
Hamilton D6, Pittsburgh Sleep Quality, Young Mania Rating Scale, Functioning Assessment Short Test (FAST), internet-based Cognition Assessment Tool (ICAT) and bloodbased inflammation markers in bloodsamples, hair cortisol and urine oxidative stress markers
Who can participate
Age group: 18-64 years Gender: Female, Male Target enrollment: 200 participants
Interventions
PLACEBO
Drug
Orimelan 3 mg tabletter
Drug
Locations 1
Denmark (1)
Technical details
Status
Active (not recruiting)
Phase
Phase 4
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Maximum age
64 Years
Healthy volunteers
No
Start date
16.01.2026
Registry ID
2025-523549-92-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.